Domainex Limited
Registered name: DOMAINEX LIMITED
Domainex Limited made £10.5m revenue and a £565k loss in the year to 31 Dec 2025. read from filing text
Domainex Limited’s revenue fell 5% to £10.5m in the year to 31 Dec 2025, with a loss of £565k and 100 employees. The company is classified under “research and experimental development on biotechnology” and is based in Pampisford; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Pampisford, East of England
- Age
- 24 yrs · since 2001
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&Lread from filing text |
| Profit & loss | ||||
| Revenue (turnover) | £10.8m | £13.3m | £11m | £10.5m |
| Cost of sales | £5m | £6.8m | £6.4m | £5.5m |
| Gross profit | £5.8m | £6.5m | £4.7m | £4.9m |
| Operating profit | £1.3m | £1.7m | −£1.3m | −£662k |
| Profit before tax | £1.2m | £1.7m | −£1.4m | −£712k |
| Profit after tax | £1.5m | £1.4m | −£1m | −£565k |
| Profit (best available) | £1.5m | £1.4m | −£1m | −£565k |
| Staff costs | £5.4m | £7.3m | £6.8m | £6m |
| Employees (average) | 93 | 124 | 117 | 100 |
| Ratios | ||||
| Profit margin | 13.8% | 10.3% | −9.5% | −5.4% |
| Gross margin | 53.5% | 48.9% | 42.4% | 47% |
| Revenue per employee | £116k | £107k | £94.3k | £105k |
| Profit per employee | £16.1k | £11.1k | −£8.9k | −£5.7k |
| Cash conversion | 111.7% | 79.4% | — | — |
| Growth (year on year) | ||||
| Revenue growth | — | ▲22.9% | ▼17.1% | ▼5.3% |
| Profit growth | — | ▼8.1% | ▼176.2% | — |
| Headcount growth | — | ▲33.3% | ▼5.7% | ▼14.5% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £3.1m | £2.6m | £974k | £458k |
| Net assets | £5.8m | £7.2m | £6.2m | £5.6m |
| Fixed assets | £3.8m | £4.5m | £4.3m | £3.4m |
| Current assets | £6.7m | £6.4m | £5.5m | £5.2m |
| Debtors | £1.7m | £1.3m | £921k | £909k |
| Deferred income | £2.1m | £1.5m | £1.7m | £856k |
| Cash from operations | £1.4m | £1.4m | −£393k | — |
| Source | FullAccounts · bulk data May 2024 | FullAccounts · bulk data May 2024 | FullAccounts · bulk data Mar 2025 | FullAccounts · bulk data Sep 2026 |
How the business works
- Profit margin
- −5.4%
- Profit ÷ revenue.
- Gross margin
- 47%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £105k
- Revenue ÷ average employees.
- Profit per employee
- −£5.7k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 32.7%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 8.2%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 8.7%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼9%
- Now £5.6m
- Cash at bank
- ▼53%
- Now £458k
- Headcount
- ▼15%
- Now 100
- Deferred income
- ▼49%
- Now £856k
- Fixed assets
- ▼20%
- Now £3.4m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Subsidiaries (1)
- Nce-Discovery LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Biopharma Process Systems LimitedWinchester · Research and experimental development on biotechnology
- Revenue
- £10.1m
- Profit
- £142k
- Staff
- 66
- Flatiron Health UK LtdST Albans · Research and experimental development on biotechnology
- Revenue
- £9.5m
- Profit
- £239k
- Staff
- 32
- Askbio UK LtdMidlothian · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £1.8m
- Staff
- 54
- Dna Legal LimitedFrome · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £3.2m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
- Theradex (Europe) LimitedRedhill · Research and experimental development on biotechnology
- Revenue
- £15.2m
- Profit
- £3.1m
- Staff
- 43
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£565k), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.